How Many People Have Taken Ozempic: Unpacking the GLP-1 Phenomenon and Personalized Weight Management

Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide and tirzepatide have become household names in weight management, with clinical studies showing that approximately 15-20% of U.S. adults have either used or considered GLP-1 therapy. Behind this surge lies a straightforward principle: these medications help regulate appetite and blood sugar, making weight loss more achievable. Yet individual responses vary dramatically, which is why PlexusDx focuses on matching each patient with the medication and dose that fits their unique body chemistry.

The Rising Demand for GLP-1 Weight Loss Treatment

Global interest in GLP-1 therapy has grown exponentially over the past three years. Pharmacy data indicates that millions of prescriptions have been filled in the United States alone, with demand continuing to accelerate as more people learn about weight loss outcomes. This popularity reflects both the clinical effectiveness demonstrated in major trials and the growing recognition that weight management requires medical-grade support for many individuals.

Insurance coverage limitations and supply chain challenges have created barriers to access for many patients seeking GLP-1 therapy. PlexusDx addresses this gap by offering compounded semaglutide and tirzepatide through licensed 503A compounding pharmacies, serving all 50 states without requiring insurance or membership fees. This approach ensures that cost and logistics no longer prevent qualified individuals from accessing these proven medications.

Understanding GLP-1 Medication Options and Mechanisms

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone that signals fullness to the brain and slows stomach emptying. Semaglutide and tirzepatide are the two most commonly prescribed compounds in this class, with tirzepatide also activating GIP receptors for a dual mechanism of action. Both medications improve fasting blood sugar, reduce cravings, and promote sustainable weight loss when combined with lifestyle modifications.

PlexusDx offers multiple delivery methods and formulations to match patient preferences and tolerability. Injection options include compounded semaglutide starting at $149/month and compounded tirzepatide starting at $249/month, while oral semaglutide begins at $249/month and oral tirzepatide at $279/month. The GLP-Squared Injection, a dual-compound option combining semaglutide and tirzepatide, starts at $249/month for patients seeking enhanced efficacy. Your dose may need to go up. Your price won't.

Why Genetic Testing Improves GLP-1 Treatment Outcomes

Not every patient responds identically to GLP-1 therapy, and genetics play a significant role in medication efficacy and side effect tolerance. Key genetic variants in the GLP1R, GIPR, FTO, and MC4R genes influence how your body processes appetite signals and metabolizes these compounds. PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways across 49 peptides, providing 150+ genetic insights that guide personalized medication selection and dosing strategies.

The Precision Peptide Genetic Test costs $99 as an add-on after your first month of treatment. This testing maps your unique peptide-pathway genetics—distinct from pharmacogenomic testing—to predict which GLP-1 formulation and approach will deliver the best results for your body. Patients with genetic predispositions toward stronger GLP-1 receptor responsiveness, for example, may achieve target weight loss at lower doses, while others may benefit from dual-compound therapy or alternative peptide protocols.

Comparing Compounded GLP-1 to Commercial Alternatives

Commercial semaglutide and tirzepatide products face manufacturing constraints that drive up costs and limit availability. Compounded medications from licensed 503A pharmacies offer equivalent active ingredients at lower price points while maintaining rigorous quality standards. PlexusDx partners exclusively with licensed 503A compounding pharmacies—never 503B—ensuring pharmaceutical-grade preparation tailored to individual patient needs.

Cost and accessibility remain critical considerations for patients committing to long-term weight management. PlexusDx medications are HSA/FSA eligible, require no insurance approval, and come with no hidden membership fees. Monthly pricing remains flat regardless of dose adjustments, so as your treatment progresses and your dose increases, your out-of-pocket expense stays predictable. This transparent pricing model makes sustained GLP-1 therapy financially sustainable for more patients.

Building a Sustainable Weight Loss Plan with Personalized Peptide Science

Medication alone does not guarantee lasting weight loss. The most successful outcomes combine GLP-1 therapy with consistent nutrition habits, regular physical activity, and behavioral support. PlexusDx guides patients through this comprehensive approach by identifying which medication and dose aligns with their genetic profile, lifestyle capacity, and weight loss goals.

Starting with the Microdose GLP-1 Protocol at $129/month allows patients to assess tolerability before committing to higher-dose semaglutide or tirzepatide. Once you've completed one month of treatment, adding the Precision Peptide Genetic Test ($99) reveals which peptide pathways drive your appetite, satiety, and metabolism, informing whether you'll benefit most from oral therapy, injectable therapy, or a dual-compound approach. This data-driven strategy maximizes both efficacy and patient satisfaction.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Precision Peptide Genetic Test starts at $99 add-on. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How many people have actually used Ozempic or similar GLP-1 medications?

Approximately 15-20% of U.S. adults have either used or considered GLP-1 therapy, with millions of prescriptions filled annually. Global demand continues rising as clinical evidence of weight loss and metabolic benefits spreads. PlexusDx serves this growing population by providing accessible compounded alternatives to commercial products through licensed 503A pharmacies across all 50 states.

What is the difference between semaglutide and tirzepatide?

Semaglutide activates GLP-1 receptors alone, while tirzepatide activates both GLP-1 and GIP receptors for a dual mechanism of action. Clinical trials show tirzepatide produces slightly greater weight loss on average, but individual responses vary based on genetics and lifestyle. PlexusDx Precision Peptide Genetic Test can help predict which compound will work best for your unique peptide-pathway profile.

Why is PlexusDx compounded GLP-1 more affordable than brand-name products?

Compounded medications from licensed 503A pharmacies bypass manufacturing and brand-marketing costs, allowing PlexusDx to offer compounded semaglutide starting at $149/month and tirzepatide at $249/month without insurance. All pricing is flat per compound across commitment tiers, meaning your dose can increase without increasing your monthly cost.

Are there side effects with GLP-1 therapy, and how can genetic testing help?

Common side effects include nausea, constipation, and mild fatigue, which typically improve as your body adjusts. The Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes to predict your likely tolerability profile and optimal dose range. Patients with certain genetic predispositions may experience fewer side effects at lower doses or benefit from alternative formulations like oral therapy.

What does the Precision Peptide Genetic Test reveal about my treatment?

The $99 add-on test maps 14 metabolic pathways and 49 peptides to generate 150+ genetic insights specific to appetite regulation, satiety signaling, and GLP-1 receptor responsiveness. Results guide whether you'll respond best to semaglutide, tirzepatide, a dual-compound approach, or PlexusDx's Microdose protocol, personalizing your entire weight loss strategy.

Related Reading

• Glp 1 For Losing Weight
• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After
• Glp 1 Dosage For Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.